Peter Emtage, Santa Ana Bio CEO (Versant)

Ver­san­t's new im­munol­o­gy biotech San­ta Ana Bio snags Se­ries A with GV, TPG part­ners on board

Pro­lif­ic biotech in­vestor Ver­sant Ven­tures is brew­ing an­oth­er start­up, this time im­munol­o­gy play­er San­ta Ana Bio, whose board in­cludes part­ners from GV and TPG.

On its web­site, the Cal­i­for­nia biotech says it has re­cent­ly closed a Se­ries A fi­nanc­ing. An SEC fil­ing from last month out­lined plans for a $70 mil­lion round af­ter seek­ing a $42 mil­lion eq­ui­ty raise in 2021.

The com­pa­ny, led by CEO Pe­ter Em­tage, de­clined an in­ter­view and said it will come out of stealth lat­er this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.